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Backgrounds: Adenocarcinoma in situ (AIS) of the lung has an extremely favorable prognosis. However, early but
invasive adenocarcinoma (eIA) sometimes has a fatal outcome. We had previously compared the expression profiles
of AIS with those of eIA showing lymph node metastasis or a fatal outcome, and found that stratifin (SFN, 14-3-3
sigma) was a differentially expressed gene related to cell proliferation. Here, we performed an in vivo study to clarify
the role of SFN in initiation and progression of lung adenocarcinoma.
Findings: Suppression of SFN expression in A549 (a human lung adenocarcinoma cell line) by siSFN significantly
reduced cell proliferation activity and the S-phase subpopulation. In vivo, tumor development or metastasis to the
lung was reduced in shSFN-transfected A549 cells. Moreover, we generated SFN-transgenic mice (Tg-SPC-SFN+/−)
showing lung-specific expression of human SFN under the control of a tissue-specific enhancer, the SPC promoter.
We found that Tg-SPC-SFN+/− mice developed lung tumors at a significantly higher rate than control mice after
administration of chemical carcinogen, NNK. Interestingly, several Tg-SPC-SFN+/− mice developed tumors without
NNK. These tumor cells showed high hSFN expression.
Conclusion: These results suggest that SFN facilitates lung tumor development and progression. SFN appears to be
a novel oncogene with potential as a therapeutic target.
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Lung cancer is the most common cause of global
cancer-related mortality, and the most common histo-
logical type is adenocarcinoma [1]. Noguchi et al. [2]
have demonstrated that adenocarcinoma in situ (AIS)
has an extremely favorable prognosis, with a 5-year sur-
vival rate of 100 %. AIS shows stepwise progression to
early but invasive adenocarcinoma (eIA), which has a
relatively poorer outcome, the 5-year survival rate being
75 % [2, 3]. We previously compared the gene expres-
sion profiles of AIS with those of eIA associated with
lymph node metastasis or a fatal outcome, and screened
the differentially expressed genes by cDNA microarray.
Among genes showing significantly higher expression
in eIA than in AIS, we finally focused on stratifin
(SFN, 14-3-3 sigma) [4], and subsequently clarified* Correspondence: nmasayuk@md.tsukuba.ac.jp
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creativecommons.org/publicdomain/zero/1.0/that its overexpression in eIA is associated with de-
methylation of its promoter region [5].
14-3-3 is a highly conserved, ubiquitously expressed
protein family, associated with many different cellular
processes. Among the seven human 14-3-3 isoforms
(beta, epsilon, eta, gamma, tau, zeta, and sigma), 14-3-3
sigma has been linked to cancer most directly. 14-3-3
sigma (SFN) was originally identified as a p53-inducible
gene that is responsive to DNA-damaging agents [6, 7].
These findings define SFN as a negative regulator of cell
cycle progression. However, our analysis of SFN expres-
sion in lung adenocarcinoma indicated that it is overex-
pressed in tumor cells to a greater extent than in normal
lung epithelium, and that this overexpression stimulates
tumor growth [4]. On the basis of these findings, we
speculate that SFN in lung adenocarcinoma cells might
have tissue-specific functions and regulate cell cycle pro-
gression in a positive manner.
Here, we first examined the function of SFN in lung
adenocarcinoma cells. All materials and methods ares article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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cinoma cell line A549 transfected with siSFN, cell prolif-
eration, invasiveness, apoptosis, and senescence were
analyzed respectively. Suppression of SFN led to a signifi-
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tosis or senescence [8, 9], we were unable to detect any
such association in the present study. This is likely because
SFN does not bind to proteins such as BAX or BAD, which
regulate apoptosis or senescence in lung adenocarcinoma
(data not shown, personal communication). We are investi-
gating the functional network of SFN in lung adenocarcin-
oma, and the results will be published in the near future.
We next induced stable knockdown of SFN using
two individual shRNAs (shSFN#1 and shSFN#2). These
shRNAs significantly inhibited the expression of SFN
in A549 (Fig. 1d) and reduced the degree of cell growth
(Fig. 1e). To evaluate the oncogenic activity of SFN, we
injected A549-shSFN#1 and -shSFN#2 intrabronchially
into SCID mice, and at 4 weeks after injection [10], all
the mice were sacrificed and their lungs were collected.
It was found that A549-shSFN#1 and A549-shSFN#2
formed significantly fewer tumors than the control cells
(Table 1). Whereas the mice injected with A549-shLuc de-
veloped tumors up to 4 mm in size and the number of such
tumors was high, the mice injected with A549-shSFN#2 de-
veloped just one tumor each, and each tumor was less than
1 mm in size (Fig. 1f). SFN expression was suppressed in the
tumors that developed in the A549-shSFN#2 group relative
to those that developed in the A549-shLuc group (Fig. 1f).
Moreover, in order to examine the effect of SFN on the
metastatic potential of lung adenocarcinoma cells, we
intravenously injected A549-shSFN#1 and -shSFN#2 into
SCID mice, and sacrificed the mice 8 weeks after injection.
We found that A549-shSFN#1 and A549-shSFN#2 did
not form any tumors, whereas control cells formed nu-
merous poorly differentiated adenocarcinomas in the
lungs (Fig. 1g, Table 1). These data indicated that knock-
down of SFN suppressed not only lung tumor formation
but also the metastatic potential of lung adenocarcinoma.
While down-regulation of SFN in vitro had no effect
on cancer cell migration and invasion (Additional file 3:
Figure S2), suppression of SFN expression reduced the
dissemination/metastasis of xenograft tumors (Table 1).
Although the results of the in vitro and in vivo assays
appear contradictory, we consider that growth reductionTable 1 Tumorigenicity of A549-shSFN in SCID mice
shRNA T (%) D (%) DM (%)
Intrabronchial shSFN#1 0/4 (0) 0/4 (0) 0/4 (0)
(n = 4) shSFN#2 2/4 (50) 0/4 (0) 0/4 (0)
shLuc 4/4 (100) 1/4 (25) 0/4 (0)
Intravenous shSFN#1 0/4 (0) 0/4 (0) 0/4 (0)
(n = 4) shSFN#2 0/4 (0) 0/4 (0) 0/4 (0)
shLuc 4/4 (100) 3/4 (75) 0/4 (0)
T tumor development, D intrathoracic dissemination by gross appearance,
DM distant metastasis. Liver and brain were analyzed as examples of common
sites of lung cancer metastasisof A549-shSFN reduced the activity of the tumor cells
in mice and finally affected their metastatic or invasive
capacity.
Next, to generate transgenic mice exhibiting lung-
specific expression of human SFN (hSFN), we ligated a
fragment of the surfactant protein C (SPC) promoter to
a cDNA for hSFN (Fig. 2a), which was attached to a
polyadenylation signal. The transgenic DNA was then
injected into pronuclear-stage embryos of ICR (Institute
of Cancer Research) mice, and the resulting offspring
were screened by genotyping PCR for the presence of the
transgene. Twelve founder mice positive for transgene in-
tegration were obtained. To confirm the lung-specific ex-
pression of the transgene, we performed RT-PCR and IHC
to detect hSFN mRNA and protein in the F1 mice. The
transgene was expressed in lung tissue (type II alveolar
epithelial cells and basal cells in bronchial wall) but not in
heart, kidney, liver, or spleen (Fig. 2b, c). We selected two
lines that showed the highest hSFN expression in lung
(lines 109 and 130, Additional file 4: Figure S3).
4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK),
a tobacco-specific and highly potent pulmonary carci-
nogen, induces lung adenoma and adenocarcinoma
in various species [11]. Our preliminary experiment
showed that 18 % of WT ICR mice developed lung
tumors 20 weeks after intraperitoneal (i.p.) administra-
tion of NNK. In order to observe the tumorigenic
activity of SFN, Tg-SPC-SFN+/− and WT ICR mice were
i.p. administered 4 mg NNK, or saline as a control, and
tumorigenicity was assessed for 20 weeks. Lungs of
representative mice were periodically examined using
animal CT. This revealed that some Tg-SPC-SFN+/−
developed pulmonary tumors from 15 weeks after NNK
administration (Fig. 2d). At 20 weeks after NNK admin-
istration, 47.8 % of Tg-SPC-SFN+/− (11/23) had devel-
oped lung tumors, whereas only 11.1 % of WT ICR
(3/27) had done so (Table 2, Fig. 2e). This difference
in the incidence of lung tumors was statistically sig-
nificant (p <0.001, χ2 test). One Tg-SPC-SFN+/− mouse
developed three tumors, and another developed two
simultaneously. The others developed one tumor each.
Histologically, all of the tumors were poorly differenti-
ated adenocarcinoma, but intrathoracic dissemination
or metastasis was not observed until 20 weeks after
NNK administration. Independent evaluation of male
and female mice revealed no significant gender differ-
ence. Although it is possible that the transgene could
have disrupted a locus leading to increased suscep-
tibility to tumor formation, we consider that tumor
formation in Tg-SPC-SFN+/− was caused by hSFN over-
expression because we also performed the same experi-
ment using two transgenic lines independently, and the
results were similar. All of the tumors that developed





Fig. 2 (See legend on next page.)
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Fig. 2 Generation of Tg-SPC-SFN+/−. a A cDNA for SFN was inserted between the SPC promoter and both the splicing and polyadenylation
(polyA) signal sequences. b RT-PCR using cDNA extracted from lung, heart, kidney, liver, and spleen of representative Tg-SPC-SFN+/− mice. c hSFN
IHC using FFPE specimens of each of the organs from representative Tg-SPC-SFN+/− mice. Transgene expression (hSFN) was detected only in lung.
Magnification: ×200. d CT image of representative Tg-SPC-SFN+/− lungs 10, 15, and 20 weeks after NNK administration. Arrows indicate suspected
tumors. Scale bar: 10 mm. e Gross appearance of lungs of Tg-SPC-SFN+/− mice administered NNK (1) and saline (2). Arrows indicates tumors. Scale
bar: 5 mm. f hSFN IHC using FFPE specimens of tumors and adjacent normal lung from Tg-SPC-SFN+/−mice. Magnification: ×200
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no hSFN expression, but slight mSFN expression
(Additional file 5: Figure S4).
Surprisingly, two of seven Tg-SPC-SFN+/− mice
(28.6 %) developed tumors even though they were not
administered NNK (Table 2, Fig. 2e). These results
indicate that SFN facilitates not only tumor progression
but also tumor initiation, and that it works as an onco-
gene. Soda et al. found that 100 % of Tg-EML4-ALK
mice developed hundreds of adenocarcinoma nodules in
both lungs within a few weeks after birth [12]. Although
the oncogenic activity of SFN is weaker than that of
EML4-ALK fusion kinase, SFN also appears to have the
potential to initiate lung adenocarcinoma.
A number of driver oncogenes have been reported,
and many patients with lung adenocarcinoma are treated
using various drugs targeting these oncogenes. Although
these targeting drugs are initially effective, most cancers
develop tolerance to them [13]. This phenomenon can
be explained by complex alterations of oncogenes and
anti-oncogenes in lung adenocarcinoma at the advanced
stage [14]. However, according to the multistep carcino-
genesis of lung adenocarcinoma [15], the number of
such driver oncogenes in early-stage lung adenocarcin-
oma is expected to be limited, and SFN overexpression
is one of the candidates suggested playing an important
role in forced cell proliferation. During the course of slow
but steady cell proliferation, tumor cells acquire several
crucial gene alterations such as ALK translocation, p53
mutation and EGFR amplification. In the present study,
we demonstrated that SFN is an oncogenic factor playing
a role in the initiation and progression of early lungTable 2 Tumorigenicity of lung adenocarcinoma in Tg-SPC-SFN+/−
mice
Genotype Wild type Tg-SPC-SFN+/−
i.p. Saline NNK Saline NNK
Nodule count
0 7 24 5 12
1 0 3 1 10
2 0 0 1 0
3 0 0 0 1
Total 7 27 7 23
Proportion of mice with tumor(s) 0 11.1 % 28.6 % 47.8 %adenocarcinoma. Since alteration of SFN is observed
in most lung adenocarcinomas, even AIS and minimally
invasive adenocarcinoma, targeted therapy to block SFN
might be a new treatment strategy for patients with early-
stage lung adenocarcinoma. Although the mechanism
underlying the function of SFN in lung adenocarcinoma
progression has not been proved, further analysis of the
molecular network of SFN in lung tumor cells is required.Additional files
Additional file 1: Materials and Methods. (DOCX 20 kb)
Additional file 2: Figure S1. Confirmation of the effect of specific
siRNA for SFN. A) Relative SFN mRNA expression was analyzed by
real-time RT-PCR. A549, A549 transfected with siSFN or siCNT. Although
there was no difference in SFN expression between A549 and siCNT,
SFN was strongly suppressed in siSFN. B) Relative SFN mRNA expression
was analyzed 24, 48, and 72 h after siRNA transfection. siSFN
continuously suppressed SFN expression for at least 72 h. (PDF 129 kb)
Additional file 3: Figure S2. Functional analysis of SFN using A549
cells transfected with siSFN. A) Invasion assay was performed using A549
cells transfected with siSFN and incubated at 37 °C for 48 h. There was
no significant difference between siSFN and siCNT. B) Scratch assay to
assess migration [16]. A scratch wound was created by scraping the cell
monolayer with a sterile 100-μL pipette, and the wounded cultures were
then incubated at 37 °C for 16 h. Migrating cells in the wound area were
photographed using a microscope and the size of the remaining wound
was measured. Assays were performed three times using triplicate wells.
C) Caspase-3/7 assay to assess apoptosis. A549 cells were transfected with
siSFN and incubated at 37 °C for 48 h. UV-irradiated Jurkat cells as a
positive control and unirradiated Jurkat cells as a negative control were
also analyzed. D) Senescence-associated β-galactosidase (SA-β-Gal) assay
to assess senescence. A549 cells were transfected with siSFN and
incubated at 37 °C for 24 or 48 h. Quantification was performed by
counting the positive cells present in 20 independent fields of view
at × 10 magnification. *: p >0.05. (PDF 184 kb)
Additional file 4: Figure S3. hSFN IHC using FFPE specimens of normal
lung tissue from F1 Tg-SPC-SFN+/− mice of 12 founder mice. Anti-hSFN
antibody with no mouse cross-reactivity (Bethyl Laboratories,
Montgomery, TX) was used as the first antibody. PC indicates positive
control (A549 xenograft in nude mice), and NC indicates negative control
(WT ICR mice). Lines 109 and 130 were selected for further analysis.
Magnification: ×200. (PDF 392 kb)
Additional file 5: Figure S4. SFN IHC using WT ICR-administered NNK.
Anti-hSFN antibody with mouse cross-reactivity (IBL, Gumma, Japan) was
used as the first antibody. Slight mSFN expression was detected only in
tumor cells. (PDF 209 kb)Abbreviations
SFN: Stratifin; SCID: Severe combined immunodeficiency; ICR: Institute of
Cancer Research; NNK: 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone;
SPC: Surfactant protein C; Tg: Transgenic mice; WT: Wild type; eIA: early
invasive adenocarcinoma; AIS: Adenocarcinoma in situ;
IHC: Immunohistochemistry.
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